Cue Biopharma, Inc.
corporate_fare Company Profile
Cue Biopharma, Inc. (NASDAQ:CUE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for CUE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for CUE spans 8-K, 10-Q, 4, S-3.
Recent high-impact activity:
- Cue Biopharma Posts $50M Q3 Loss, $57.9M Cash, New CUE-221 Subgroup Data
- Cue Biopharma Posts $50M Third-Quarter Loss
- CUE-221 Phase 2 CSU Data: 54% Complete Hives Resolution vs 11% Placebo, Durable 12 Weeks Off Drug
- Cue Biopharma Surges 51% Premarket on Positive Phase 2 CSU Data
- Cue Biopharma's CUE-221 Hits Primary Endpoint in Phase 2 CSU Trial, Beats Xolair
Financial Snapshot
Short Interest & Short Volume
7.57 days to coverFINRA reported short interest of 862,798 shares in CUE as of the October 30, 2026 settlement, a 8.9% increase from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 50.1% of CUE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CUE, detected from its recent SEC filings · based on capital-structure filings through 2026-07-10.
$50M Private Placement · Dilution Impact
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →